Stockscreener 앱 받기
2.50
3.10%
-0.08
시간 외 거래:
2.46
-0.04
-1.60%
전일 마감가:
$2.58
열려 있는:
$2.67
하루 거래량:
3.32M
Relative Volume:
2.35
시가총액:
$177.52M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-0.9363
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
+17.92%
1개월 성능:
+46.20%
6개월 성능:
-29.58%
1년 성능:
-56.82%
1일 변동 폭
$2.44
$2.94
1주일 범위
$1.95
$2.94
52주 변동 폭
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.50 | 139.17M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 2025 Q2 Earnings Widened Losses Amid Mixed Price Performance - AInvest
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M - simplywall.st
C4 Therapeutics Reports Q2 2025 Financial Results - TipRanks
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Q2 2025 Financial Results: Revenue Down to $6.5M, Cash Position at $223M - AInvest
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
C4 Therapeutics, Inc. SEC 10-Q Report - TradingView
C4 Therapeutics reports Q2 2025 results, cemsidomide Phase 1 data accepted at IMS. - AInvest
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What drives C4 Therapeutics Inc. stock priceBuild wealth faster with disciplined trading - Jammu Links News
Is it the right time to buy C4 Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
What makes C4 Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
What is C4 Therapeutics Inc. company’s growth strategyMaximize returns with strategic trading plans - Jammu Links News
When is C4 Therapeutics Inc. stock expected to show significant growthGet timely alerts on top market movers - Jammu Links News
What is the dividend policy of C4 Therapeutics Inc. stockUnlock daily trading alerts for profits - Jammu Links News
Is C4 Therapeutics Inc. stock overvalued or undervaluedSuperior stock growth - Jammu Links News
Why is C4 Therapeutics Inc. stock attracting strong analyst attentionUnmatched market performance - Jammu Links News
Is C4 Therapeutics Inc. a growth stock or a value stockFree Capital Allocation Plans - Jammu Links News
What are C4 Therapeutics Inc. company’s key revenue driversGet alerts on high-potential market moves - Jammu Links News
What is the risk reward ratio of investing in C4 Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
What are the latest earnings results for C4 Therapeutics Inc.Invest confidently with professional market insights - Jammu Links News
What are analysts’ price targets for C4 Therapeutics Inc. in the next 12 monthsInvest confidently with market-leading analysis - Jammu Links News
Here's What Analysts Are Forecasting For C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its First-Quarter Results - 富途牛牛
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Protara Therapeutics Grants $45K Worth of Stock Options and RSUs to Strategic New Employees - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Expands Team with Strategic Stock Grants Worth 18,200 Shares - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Does C4 Therapeutics Inc. stock perform well during market downturnsAdvanced Screener Report With High Returns - Jammu Links News
Sentiment analysis tools applied to C4 Therapeutics Inc.Short Term Setup With Predictive Chart Confirmed - metal.it
C4 Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Community Strategy With High Win Rate Backtested - metal.it
Published on: 2025-07-29 21:44:21 - metal.it
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):